Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Week in Review

Summaries of each week's events in China biotech are provided free to all readers.  A weekly email newsletter providing direct links to these articles is also available - click here for free email newsletter...

Week in Review: Hengrui and Dearon Announce $7.2 Billion in Drug Licensings

Week in Review: Takeda Options Alzheimer's Therapy from AC Immune in $2.2 Billion Deal

Week in Review: Week in Review: Sciwind, Sino Biological and Biocytogen Announce Deals

Week in Review: D3 Bio Raises $62 Million for Trials of KRAS G12C Inhibitor

Week in Review: ProfoundBio, a Seattle-Suzhou ADC Biotech, Acquired by Genmab for $1.8 Billion

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital